In this InvestorIntel interview, Tracy Weslosky talks with Zentek Ltd.‘s (NASDAQ: ZTEK | TSXV: ZEN) CEO and Director Greg Fenton about an update on the commercialization of Zentek’s patented ZenGUARD™ antimicrobial technology.

With the ability to increase viral filtration efficiency of an HVAC (Heating, Ventilation, and Air Conditioning) filter by almost 5 times, Greg explains how a ZenGUARD™ coated HVAC filter is an incredibly safe way to improve indoor air quality and remove pathogens from the air without any additional energy requirements.

Although currently going through a regulatory approval process through Health Canada’s Pest Management Regulatory Agency (“PMRA”) in Canada, ZenGUARD™ has already received approval from another branch of Health Canada, indicating a high likelihood of approval from PMRA. Greg also discusses how ZenGUARD™ is seeing a growing demand from end users including filter manufacturers, provincial and municipal governments, and private sector customers.

To access the full InvestorIntel interview, click here

Don’t miss other InvestorIntel interviews. Subscribe to the InvestorIntel YouTube channel by clicking here.

About Zentek Ltd.

Zentek is a graphene technology company focused on the research, development, and commercialization of graphene-based novel products to give its commercial partners a competitive advantage by making their products better, safer, and greener.

Zentek’s patented ZenGUARD™ coating is shown to have 99-per-cent anti-microbial activity and to significantly increase the bacterial and viral filtration efficiency of both surgical masks and HVAC systems. Zentek’s ZenGUARD™ production facility is located in Guelph, Ont. Zentek’s second technology is the patent-pending ZenARMOR™ platform focused on corrosion protection applications.

To know more about Zentek Ltd., click here

Disclaimer: Zentek Ltd. is an advertorial member of InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp., (IIC), does not contain, nor does it purport to contain, a summary of all the material information concerning the “Company” being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company’s profile on Sedar.com and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at [email protected].

In this InvestorIntel interview, Tracy Weslosky talks to Zentek Ltd.‘s (NASDAQ: ZTEK | TSXV: ZEN) CEO and Director Greg Fenton about receiving the final report for Phase 2 testing of ZenGUARD™ for use in Heating, Ventilation and Air Conditioning (“HVAC”) filtration. Used as an antimicrobial coating, Greg discusses how ZenGUARD™ is a “best in class solution” to improve indoor air quality and remove pathogens from air, including SARS-CoV-2 (virus that causes COVID-19).

With ability to increase efficiency of a MERV 8 filter by almost 5 times, Greg discusses how ZenGUARD™ coating can be applied to existing HVAC filters without having to do any modification to the HVAC systems. Having shared the Phase 2 report with Federal and Provincial organizations, Greg goes on to provide an update on commercialization of ZenGUARD™ coated HVAC filters.

To access the full InvestorIntel interview, click here

Don’t miss other InvestorIntel interviews. Subscribe to the InvestorIntel YouTube channel by clicking here.

About Zentek Ltd.

Zentek is an IP development and commercialization company focused on the research, development and commercialization of novel products using graphene and nanomaterials for use in the healthcare industry and beyond.

Zentek’s patented ZenGUARD™ coating is shown to have 99% antimicrobial activity and to significantly increase the bacterial and viral filtration efficiency of both surgical masks and HVAC systems. Zentek’s ZenGUARD™ production facility is located in Guelph, Ontario.

To know more about Zentek Ltd., click here

Disclaimer: Zentek Ltd. is an advertorial member of InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp., (IIC), does not contain, nor does it purport to contain, a summary of all the material information concerning the “Company” being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company’s profile on Sedar.com and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at [email protected].

In this InvestorIntel interview, Tracy Weslosky has Zentek Ltd.‘s (NASDAQ: ZTEK | TSXV: ZEN) CEO and Director Greg Fenton discuss Zentek’s recent news release on the ZenGUARD™ technology patent being granted. As an antimicrobial coating used on personal protective equipment (PPE) and heating, ventilation, and air conditioning (HVAC) applications, Greg explains how they took ZenGUARD™ from a concept in the lab to an Intellectual Property that can be commercialized.

Greg goes on to provide an update on the successful completion of Phase 2 HVAC filter testing of the ZenGUARD™ coating by the National Research Council of Canada. As an economical solution to significantly reduce airborne pathogens and improve indoor air quality, Greg discusses how ZenGUARD™ coating can be applied to HVAC filters without any modification to existing HVAC systems.

To access the full InvestorIntel interview, click here

Don’t miss other InvestorIntel interviews. Subscribe to the InvestorIntel YouTube channel by clicking here.

About Zentek Ltd.

Zentek is an IP development and commercialization company focused on the research, development and commercialization of novel products using graphene and nanomaterials for use in the healthcare industry and beyond.

Zentek’s patented ZenGUARD™ coating is shown to have 99% antimicrobial activity, including against COVID-19, for use in PPE and potentially HVAC systems and other industries. Zentek’s ZenGUARD™ production facility is located in Guelph, Ontario.

To know more about Zentek Ltd., click here

Disclaimer: Zentek Ltd. is an advertorial member of InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp., (IIC), does not contain, nor does it purport to contain, a summary of all the material information concerning the “Company” being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company’s profile on Sedar.com and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at [email protected].

In a recent InvestorIntel interview, Tracy Weslosky spoke with Greg Fenton, CEO and Director of Zentek Ltd. (TSXV: ZEN) about Zentek’s recent news release on receiving approval to list on the Nasdaq and about engaging Vimta Labs to begin studies of ZenGUARD™ active ingredient as a potential treatment of infectious skin disease.

In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Greg Fenton provided an update on Zentek’s “unique and innovative” ZenGUARD™ antimicrobial coating which is “proven to be more than 99% effective in reducing the physical spread of the SARS-CoV-2” and other pathogens. He went on to say that Zentek will be publishing the patent application for the ZenGUARD™ antimicrobial coating on March 21, 2022.

To watch the full interview, click here.

About Zentek Ltd.

Zentek is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection and treatment. Zentek is currently focused on commercializing ZenGUARD™, a patent-pending coating shown to have 99% effectiveness in antimicrobial activity reduction, including against the COVID-19 pathogens, and the potential to use similar compounds as products against other infectious diseases. The Company also has an exclusive agreement to be the global commercializing partner for a newly developed rapid aptamer-based pathogen detection technology.

To learn more about Zentek Ltd., click here.

Disclaimer: Zentek Ltd. is an advertorial member of InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp., (IIC), does not contain, nor does it purport to contain, a summary of all the material information concerning the “Company” being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company’s profile on Sedar.com and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at [email protected].